- Investing.com
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
Ziftomenib's Promise | Explore Kura Oncology's lead candidate ziftomenib, showing potential in acute myeloid leukemia treatment with pivotal trial results expected in Q1 2025 |
Financial Fortitude | Delve into Kura's robust financial position, with cash reserves exceeding $450 million and a strategic partnership with Kyowa Kirin bolstering resources |
Market Dynamics | Analyst price targets range from $32 to $37, reflecting optimism about Kura's potential in the competitive AML treatment landscape |
Risk vs. Reward | Learn about the challenges Kura faces, including clinical trial outcomes and regulatory hurdles, balanced against the potential for ziftomenib to become best-in-class |
Metrics to compare | KURA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKURAPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.5x | −3.4x | −0.6x | |
PEG Ratio | 0.21 | 0.06 | 0.00 | |
Price/Book | 1.6x | 1.8x | 2.6x | |
Price / LTM Sales | - | 414.1x | 3.1x | |
Upside (Analyst Target) | 214.9% | 275.0% | 48.8% | |
Fair Value Upside | Unlock | 22.4% | 7.5% | Unlock |